Page 5 - Ancer Prostate News Today

New advance builds on a rapidly growing field using ultrasound to fight cancer and disease.

A large study of Swedish men found that higher levels of cardiorespiratory fitness were associated with a lower risk of developing and dying from certain cancers.

On Saturday, CMS will launch the Enhancing Oncology Model, the second major project focused on improving quality and access to cancer care while lowering spending.

Patients with chronic lymphocytic leukemia (CLL) experience long-term progression-free survival benefits with 1 year of venetoclax plus obinutuzumab versus a chemotherapy-based regimen.

The update builds on 2019 recommendations and incorporates safety concerns about JAK inhibitors, advises on differential drug efficacy across disease manifestations, and eliminates systemic steroids.

A new NCCN survey found that most centers are experiencing shortages of carboplatin and cisplatin. The NCCN has called for strategies to address these drug shortages.

Second-generation antiandrogens for prostate cancer carry a substantial risk of cognitive problems and fatigue, and they increase the risk of falls by 87%, warn researchers.

The prevalence of actionable genes is similar across genomes of men from African, European, Asian, or mixed ancestry, suggesting that genomics alone cant account for racial disparities in outcomes.

The risk for interstitial lung disease in patients with PsA during the first 5 years was five times higher than for the general population, and the risk was not modified by methotrexate use.

The new indication adds to the PARP inhibitors previous approvals for HRR-mutated metastatic castration-resistant prostate cancer as well as for ovarian, breast, and pancreatic cancer indications.